Title:
NEW TREATMENT AND PREVENTION BASED ON NEW METHOD FOR CONTROLLING CELLULAR IMMUNITY
Document Type and Number:
WIPO Patent Application WO/2022/176920
Kind Code:
A1
Abstract:
The present disclosure provides a composition for treating or preventing a disease (for example, an infection, an allergy, or an autoimmune disease). The present disclosure provides a composition, a medicinal drug, or a kit for treating or preventing said disease in a patient. The composition, the medicinal drug, or the kit is characterized by containing a non-causative factor antigen component that is not derived from a causative factor of the disease and that does not cross-react with the causative factor. The composition is characterized by being administered in the presence of a causative factor antigen component that is derived from a causative factor of the disease to be targeted in a subject and/or that cross-reacts with the causative factor.
More Like This:
| WO/2002/040037 | M. TUBERCULOSIS CHAPERONIN 60.1 AND USES THEREOF |
| JP2005530862 | Fuel additive |
| WO/2011/150745 | MYCOBACTERIUM TUBERCULOSIS AG85AB CHIMERIC GENE VACCINE, ITS PREPARATION METHOD AND APPLICATION |
Inventors:
ISHII KEN (JP)
TEMIZOZ BURCU (JP)
KATSUNUMA KOKICHI (JP)
TEMIZOZ BURCU (JP)
KATSUNUMA KOKICHI (JP)
Application Number:
PCT/JP2022/006212
Publication Date:
August 25, 2022
Filing Date:
February 16, 2022
Export Citation:
Assignee:
ZERIA PHARM CO LTD (JP)
ISHII KEN (JP)
ISHII KEN (JP)
International Classes:
A61K39/04; A61K31/713; A61K39/00; A61K39/002; A61K39/02; A61K39/12; A61K39/145; A61K39/155; A61K39/215; A61K39/235; A61K39/39; A61K45/00; A61P31/00; A61P31/04; A61P31/12; A61P31/14; A61P37/04; A61P37/06; A61P37/08; A61P43/00
Domestic Patent References:
| WO1999045917A1 | 1999-09-16 | |||
| WO2000053203A1 | 2000-09-14 | |||
| WO2010017248A2 | 2010-02-11 |
Other References:
COUNOUPAS CLAUDIO, JOHANSEN MATT D., STELLA ALBERTO O., NGUYEN DUC H., FERGUSON ANGELA L., AGGARWAL ANUPRIYA, BHATTACHARYYA NAYAN : "A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilizing immunity against SARS-CoV-2 infection in mice", BIORXIV, 10 December 2020 (2020-12-10), pages 1 - 25, XP055959457, Retrieved from the Internet [retrieved on 20220909], DOI: 10.1101/2020.12.10.419044
SUSAN M. BUENO, PABLO A. GONZALEZ, KELLY M. CAUTIVO, JORGE E. MORA, EDUARDO D. LEIVA, HUGO E. TOBAR, GLENN J. FENNELLY, ELISEO A. : "Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 52, 30 December 2008 (2008-12-30), pages 20822 - 20827, XP002694159, ISSN: 0027-8424, DOI: 10.1073/pnas.0806244105
LEENTJENS JENNEKE, KOX MATTHIJS, STOKMAN ROBIN, GERRETSEN JELLE, DIAVATOPOULOS DIMITRI A., VAN CREVEL REINOUT, RIMMELZWAAN GUUS F.: "BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study", JOURNAL OF INFECTIOUS DISEASES, vol. 212, no. 12, 15 December 2015 (2015-12-15), US , pages 1930 - 1938, XP055959469, ISSN: 0022-1899, DOI: 10.1093/infdis/jiv332
KOBAYASHI, M. ; HERNDON, D.N. ; POLLARD, R.B. ; SUZUKI, F: "Z-100, a lipid-arabinomannan extracted from Mycobacterium tuberculosis, improves the resistance of thermally injured mice to herpes virus infections", IMMUNOLOGY LETTERS, vol. 40, no. 3, 1 June 1994 (1994-06-01), NL , pages 199 - 205, XP023669062, ISSN: 0165-2478, DOI: 10.1016/0165-2478(93)00018-9
ATSUSHI KOBAYASHI, SATOSHI KITAMURA, YOSHIKAZU KAWAKAMI, TOSHIHIRO KANKAZU, SHOJI KUDO, TSUYOSHI OGURA, MASAHIRO FUKUOKA, MICHIO Y: "Examination of clinical usefulness of Z-100 for leukopenia caused by radiotherapy As an index of protection against infection in lung cancer patients", INFLAMMATION, vol. 19, no. 5, 24 September 1999 (1999-09-24), pages 268 - 280, XP055959493, ISSN: 0389-4290, DOI: 10.2492/jsir1981.19.268
WU JUN-JUN, ZHAO LANG, HAN BEI-BEI, HU HONG-GUO, ZHANG BO-DOU, LI WEN-HAO, CHEN YONG-XIANG, LI YAN-MEI: "A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant", CHEMICAL COMMUNICATIONS0, vol. 57, no. 4, 19 January 2021 (2021-01-19), UK , pages 504 - 507, XP055959473, ISSN: 1359-7345, DOI: 10.1039/D0CC06959K
SAŁKOWSKA ANNA, KARWACIAK IWONA, KARAŚ KAJA, DASTYCH JAROSŁAW, RATAJEWSKI MARCIN: "SARS-CoV-2 Proteins Induce IFNG in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors", VACCINES, vol. 8, no. 4, 1 January 2020 (2020-01-01), pages 1 - 10, XP055959477, DOI: 10.3390/vaccines8040673
ZIRIMENYA LUDOVIKO, NKURUNUNGI GYAVIIRA, NASSUUNA JACENT, NATUKUNDA AGNES, MUTEBE ALEX, ODURU GLORIA, KABAMI GRACE, AKURUT HELLEN,: "Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme Correspondence to", BMJ OPEN, vol. 11, no. 2, 1 January 2021 (2021-01-01), London, UK , pages 1 - 7, XP055959481, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2020-040430
BURDETTE ET AL., NATURE, vol. 478, 2011, pages 515 - 8
MCWHIRTER ET AL., J. EXP. MED., vol. 206, 2009, pages 1899 - 1911
TANG ET AL., PLOS ONE, vol. 8, 2013, pages 1 - 6
HOGENESCH ET AL., FRONT. IMMUNOL., vol. 3, 2013, pages 1 - 3
MACLEOD ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 108, 2011, pages 7914 - 7919
WEERATNA ET AL., VACCINE, vol. 18, 2000, pages 1755 - 1762
DESMET ET AL., NAT. REV. IMMUNOL., vol. 12, 2012, pages 479 - 491
BARBER ET AL., IMMUNOL. REV, vol. 234, 2011, pages 99 - 108
SUN ET AL., SCIENCE, vol. 339, 2013, pages 826 - 30
ZHANG ET AL., MOL. CELL., vol. 51, 2013, pages 226 - 35
SANCHEZ AESPINOSA PGARCIA TMANCILLA R: "The 19 kDa Mycobacterium tuberculosis lipoprotein (LpqH) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor", CLIN DEV IMMUNOL, vol. 2012, 2012, pages 950503
WILLS MRCARMICHAEL AJMYNARD KJIN XWEEKES MPPLACHTER B: "Sissons JG: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL", J VIROL., vol. 70, 1996, pages 7569 - 7579, XP002060343
HARMS PRITCHARD, G., HALL, A. O., CHRISTIAN, D. A.: "Diverse roles for T-bet in the effector responses required for resistance to infection", J. IMMUNOL., vol. 194, 2015, pages 1131 - 1140
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
S. HONDA ET AL., ANAL. CHEM., vol. 52, 1980, pages 1079
SUSAN M. BUENO, PABLO A. GONZALEZ, KELLY M. CAUTIVO, JORGE E. MORA, EDUARDO D. LEIVA, HUGO E. TOBAR, GLENN J. FENNELLY, ELISEO A. : "Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 52, 30 December 2008 (2008-12-30), pages 20822 - 20827, XP002694159, ISSN: 0027-8424, DOI: 10.1073/pnas.0806244105
LEENTJENS JENNEKE, KOX MATTHIJS, STOKMAN ROBIN, GERRETSEN JELLE, DIAVATOPOULOS DIMITRI A., VAN CREVEL REINOUT, RIMMELZWAAN GUUS F.: "BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study", JOURNAL OF INFECTIOUS DISEASES, vol. 212, no. 12, 15 December 2015 (2015-12-15), US , pages 1930 - 1938, XP055959469, ISSN: 0022-1899, DOI: 10.1093/infdis/jiv332
KOBAYASHI, M. ; HERNDON, D.N. ; POLLARD, R.B. ; SUZUKI, F: "Z-100, a lipid-arabinomannan extracted from Mycobacterium tuberculosis, improves the resistance of thermally injured mice to herpes virus infections", IMMUNOLOGY LETTERS, vol. 40, no. 3, 1 June 1994 (1994-06-01), NL , pages 199 - 205, XP023669062, ISSN: 0165-2478, DOI: 10.1016/0165-2478(93)00018-9
ATSUSHI KOBAYASHI, SATOSHI KITAMURA, YOSHIKAZU KAWAKAMI, TOSHIHIRO KANKAZU, SHOJI KUDO, TSUYOSHI OGURA, MASAHIRO FUKUOKA, MICHIO Y: "Examination of clinical usefulness of Z-100 for leukopenia caused by radiotherapy As an index of protection against infection in lung cancer patients", INFLAMMATION, vol. 19, no. 5, 24 September 1999 (1999-09-24), pages 268 - 280, XP055959493, ISSN: 0389-4290, DOI: 10.2492/jsir1981.19.268
WU JUN-JUN, ZHAO LANG, HAN BEI-BEI, HU HONG-GUO, ZHANG BO-DOU, LI WEN-HAO, CHEN YONG-XIANG, LI YAN-MEI: "A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant", CHEMICAL COMMUNICATIONS0, vol. 57, no. 4, 19 January 2021 (2021-01-19), UK , pages 504 - 507, XP055959473, ISSN: 1359-7345, DOI: 10.1039/D0CC06959K
SAŁKOWSKA ANNA, KARWACIAK IWONA, KARAŚ KAJA, DASTYCH JAROSŁAW, RATAJEWSKI MARCIN: "SARS-CoV-2 Proteins Induce IFNG in Th1 Lymphocytes Generated from CD4+ Cells from Healthy, Unexposed Polish Donors", VACCINES, vol. 8, no. 4, 1 January 2020 (2020-01-01), pages 1 - 10, XP055959477, DOI: 10.3390/vaccines8040673
ZIRIMENYA LUDOVIKO, NKURUNUNGI GYAVIIRA, NASSUUNA JACENT, NATUKUNDA AGNES, MUTEBE ALEX, ODURU GLORIA, KABAMI GRACE, AKURUT HELLEN,: "Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme Correspondence to", BMJ OPEN, vol. 11, no. 2, 1 January 2021 (2021-01-01), London, UK , pages 1 - 7, XP055959481, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2020-040430
BURDETTE ET AL., NATURE, vol. 478, 2011, pages 515 - 8
MCWHIRTER ET AL., J. EXP. MED., vol. 206, 2009, pages 1899 - 1911
TANG ET AL., PLOS ONE, vol. 8, 2013, pages 1 - 6
HOGENESCH ET AL., FRONT. IMMUNOL., vol. 3, 2013, pages 1 - 3
MACLEOD ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 108, 2011, pages 7914 - 7919
WEERATNA ET AL., VACCINE, vol. 18, 2000, pages 1755 - 1762
DESMET ET AL., NAT. REV. IMMUNOL., vol. 12, 2012, pages 479 - 491
BARBER ET AL., IMMUNOL. REV, vol. 234, 2011, pages 99 - 108
SUN ET AL., SCIENCE, vol. 339, 2013, pages 826 - 30
ZHANG ET AL., MOL. CELL., vol. 51, 2013, pages 226 - 35
SANCHEZ AESPINOSA PGARCIA TMANCILLA R: "The 19 kDa Mycobacterium tuberculosis lipoprotein (LpqH) induces macrophage apoptosis through extrinsic and intrinsic pathways: a role for the mitochondrial apoptosis-inducing factor", CLIN DEV IMMUNOL, vol. 2012, 2012, pages 950503
WILLS MRCARMICHAEL AJMYNARD KJIN XWEEKES MPPLACHTER B: "Sissons JG: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL", J VIROL., vol. 70, 1996, pages 7569 - 7579, XP002060343
HARMS PRITCHARD, G., HALL, A. O., CHRISTIAN, D. A.: "Diverse roles for T-bet in the effector responses required for resistance to infection", J. IMMUNOL., vol. 194, 2015, pages 1131 - 1140
BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
S. HONDA ET AL., ANAL. CHEM., vol. 52, 1980, pages 1079
Attorney, Agent or Firm:
YAMAMOTO, Shusaku et al. (JP)
Download PDF: